Gross margins expanded from 6.7% to 8.0% year-to-date.
Net income grew 87% year-over-year despite falling sales.
Repurchased $113.5 million of common stock under authorized plan.
Extended primary credit facility maturity to 2031.
The latest filing reveals a company at a critical inflection point, attempting to trade scale for efficiency. The synthesis of the data shows a business that has successfully deleveraged and improved its cash conversion cycle, yet remains vulnerable to the same macroeconomic pressures that have historically plagued the EMS industry. The successful extension of the primary credit facility to 2031 provides the necessary breathing room for the company to execute its 'Kimball Solutions' rebranding and strategic pivot. Ultimately, the investment thesis hinges on whether the medical vertical can scale sufficiently to offset the cyclicality of the automotive and industrial markets. While the immediate financial results are impressive, the long-term trajectory will be determined by the company's ability to convert its new capacity in Indianapolis into sustainable, high-margin revenue streams without further relying on one-time restructuring gains.